Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04300829
Other study ID # ET19-084 - CICA-RT
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date June 6, 2020
Est. completion date October 9, 2022

Study information

Verified date February 2021
Source Centre Leon Berard
Contact Séverine METZGER
Phone +33 4.78.78.27.86
Email severine.metzger@lyon.unicancer.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase III, prospective, interventional, multicentric, comparative, randomized, open study with 2 parallel arms, evaluating the efficacy of Cicaderma ointment vs standard management of each site in preventing the onset of grade > 2 radiodermatitis according to the National Cancer Institute - Common Terminology Criteria for Adverse Events-Version (NCI-CTCAE-V5)


Description:

Breast cancer is the most common cancer in women. It accounts for more than 1/3 of new cancer cases and is the 1st cause of death for women. Management usually includes tumorectomy or mastectomy precede or not by a chemotherapy, then adjuvant irradiation that can be supplemented with adjuvant chemotherapy and / or hormone therapy. Radiotherapy uses ionizing radiation (photons, electrons ...) to destroy cancer cells and consists in precisely directing these radiations on the area to be treated while preserving as much as possible healthy tissues and surrounding organs. Radiation-induced dermatitis is a skin lesion that occurs after exposure to ionizing radiation and is commonly seen in patients. Acute radiodermatitis occurs in the days or weeks following the start of irradiation with different degrees of severity (dry or exsudative radiodermatitis, acute radionecrosis) They are responsible for an alteration of patients' quality of life (pain, sensitivity to UV radiation, discomfort sensations ...), which may lead to a temporary or even permanent therapeutic interruption and reduce the probability of tumor control. The management of these dermatitis is very heterogeneous, no study having demonstrated the superiority of a preventive or curative treatment. Trolamine (Biafine®) is to date the only topic with a Marketing Authorization (MA) for the treatment of radiation-induced secondary erythema. A study conducted on 254 patients at the Léon Bérard Center from 1999 to 2001 demonstrated that the preventive use of a calendula-based topical was associated with a statistically significant reduction of grade 2 radiodermitis compared to trolamine in patients presenting an early breast cancer treated with post-operative irradiation. However, this calendula ointment, which does not have the MA in the indicated indication, was in practice more difficult to apply than trolamine. Currently, skin hygiene measures to be applied are systematically explained to patients before carrying out post-operative radiotherapy (cotton clothing, neutral soap, etc.). Some centers such as Center Léon Bérard recommend the systematic use of a topic after each session, while others recommend hygiene measures or implement other options (essential oils ...). However, the effectiveness of these current practices on the prevention of radiodermatitis has not yet been demonstrated. It is a phase III, prospective, interventional, multicentric, comparative, randomized, open study with 2 parallel arms Patients will be randomized (1 :1) in Arm A (hygiene measures + preventive treatment with Cicaderma ointment) or Arm B (preventive treatment according to the site recommendations (at least the hygiene measures) with a stratification (site, body mass index ≤25 vs >25 and RT hypofractionning).


Recruitment information / eligibility

Status Recruiting
Enrollment 248
Est. completion date October 9, 2022
Est. primary completion date September 9, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years - Patient requiring a post-operative radiotherapy (post mastectomy or tumorectomy) for a mammary adenocarcinoma or an unilateral in situ breast cancer histologically documented, early stage of disease (non metastatic) - Patient with no residual tumor (R0 or R1) - Patient informed and having given her signed consent - Patient affiliated to a social security regimen Exclusion Criteria: - Unsolved cutaneous toxicities of any previous treatment - Hormonotherapy started prior to radiotherapy - Concomitant use of other topical treatments than the study treatments on the irradiated area - Patient treated by concomitant chemotherapy and/or targeted therapy - Known hypersensibility to at least one component of the topicals used or Cicadema ointment - Patient for whom follow-up does not seem possible even in the short term - Pregnant or breastfeeding woman - Participation in another clinical trial that may interfere with the evaluation of the primary endpoint - Patient Under tutorship or curatorship or deprived of liberty

Study Design


Intervention

Drug:
cicaderma + simple hygiene rules
Cicaderma ointment (2 applications / day: after the radiotherapy session) and in the evening) + simple hygiene rules
Other:
Simple hygiene rules and a maximum of one topical treatment
Simple hygiene rules according to the site recommandations including eventually a maximum of one topical treatment

Locations

Country Name City State
France Institut Sainte-Catherine Avignon
France Institut Curie Paris
France Institut Curie Saint-Cloud

Sponsors (1)

Lead Sponsor Collaborator
Centre Leon Berard

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of the Cicaderma ointment efficacy versus the standard management of each site in preventing the onset of grade >= 2 radiodermatitis (NCI-CTCAE-V5) Number of patients presenting >= 2 radiodermatitis according to the National Cancer Institute - Common Terminology Criteria for Adverse Events-Version (NCI-CTCAE-V5) Up to 30+/-4 days after the end of radiotherapy interruption
Secondary Patients' satisfaction Patients' satisfaction evaluated using the "Patient's evaluation of the preventive management of radiodermatits" - Likert scale in 5 points (from very unsatisfied to very satisfied) 30+/-4 days after the end of radiotherapy interruption
Secondary Patients' quality of life: DLQI questionnaire Patients' quality of life evaluated using the Dermatology Life Quality Index (DLQI) questionnaire (validated questionnaire composed of 10 items leading to a global score) Up to 30+/-4 days after the end of radiotherapy interruption
Secondary Patients' pain in the irradiated area: numeric scale Patients' pain evaluated using a numeric scale from 0 (no pain) to 10 (unbearable pain) Up to 30+/-4 days after the end of radiotherapy interruption
Secondary Rate of temporary or permanent RT interruption related to the onset of grade 3 radiodermatitis Temporary or permanent radiotherapy interruption related to the onset of grade 3 radiodermatitis observed during patients' treatment period Through radiotherapy completion, an average of 5 weeks
Secondary Rate of prurit onset whatever the grade Prurit onset whatever the grade observed Up to 30+/-4 days after the end of radiotherapy interruption
Secondary Doses of radiation therapy received Doses of radiation therapy received during each radiotherapy session Through radiotherapy completion, an average of 5 weeks
Secondary Delay of onset of the first cutaneous event (radiodermatitis or prurit) grade =2 Onset of the first grade >= 2 cutaneous event (radiodermatitis or prurit) Up to 30+/-4 days after the end of radiotherapy
Secondary Compliance with the Cicaderma ointment application (experimental arm) Compliance evaluated according to the ointment tubes brought back by the patients (not used or partially used) and patient's diary Up to 30+/-4 days after the end of radiotherapy
Secondary Determination of the factors measured prior to treatment initiation which are associated to the onset of grade =2 radiodermatitis (cup size) Cup size At inclusion
Secondary Determination of the factors measured prior to treatment initiation which are associated to the onset of grade =2 radiodermatitis (phototype) Phototype At inclusion
See also
  Status Clinical Trial Phase
Completed NCT04059809 - Photobiomodulation for Breast Cancer Radiodermatitis Phase 2/Phase 3
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT02058550 - Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy Phase 1
Completed NCT01399372 - Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma Phase 2
Completed NCT01434290 - Radiation Therapy in Treating Patients With Prostate Cancer Phase 2
Active, not recruiting NCT00087815 - Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain N/A
Completed NCT01407770 - Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer
Completed NCT00003313 - Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer Phase 3
Completed NCT03783364 - Pre- or Postoperative Accelerated Radiotherapy N/A
Enrolling by invitation NCT04305613 - Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
Recruiting NCT06036706 - Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma: N/A
Withdrawn NCT04593914 - A Novel Skin Barrier Protectant for Acute Radiodermatitis N/A
Recruiting NCT04110223 - Validation Studies of Biomarkers for Precision Radiation Oncology in Locally Advanced Solid Tumors
Active, not recruiting NCT02259218 - Metabolomic and Epigenetic Profiling of Bodyfluids From Lung and Brain Cancer Receiving Radiation Therapy
Recruiting NCT06073509 - Atrial Fibrillation and Other Cardiac Arrhythmias and Diseases After Radiotherapy for Breast Cancer : Watch Your HeaRT
Withdrawn NCT02017925 - Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation N/A
Completed NCT01170299 - Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer N/A
Completed NCT00974168 - Spinal Cord Compression Re-Treat Study Phase 2
Completed NCT00008398 - Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Phase 3
Enrolling by invitation NCT04047823 - Temperature and Injury in Radiotherapy Radiation Skin Injury